CAR-T Cell Therapy Market Size & Share Growth Forecast Report (2026-2035)

CAR-T Cell Therapy Market Overview

The CAR-T cell therapy market was valued at about USD 4.20 billion in 2025 and is expected to reach around USD 4.77 billion in 2026, rising to roughly USD 15.05 billion in 2035, growing at approximately 13.63% CAGR from 2026 to 2035.

Research Highlights

• CD19 held 46.05% in 2025 supported by established approvals across major B-cell malignancies.
• Autologous CAR-T held 91.25% in 2025 backed by mature commercial products and regulatory pathways.
• Lymphoma accounted for 54.05% in 2025 due to broad clinical adoption and reimbursement.
• BCMA therapies are projected at 14.02% CAGR owing to expanding multiple-myeloma treatment applications.
• North America held 52.10% in 2025 supported by established reimbursement and treatment-center infrastructure.

One of the major factors leading to the increase of the market is the worldwide rise in the number of cancer cases and the increasing number of approved treatments in the field of oncology. As per WHO and IARC data, the global incidence of cancer was 20.6 million cases in 2024. It is expected to grow further and almost double to 35 million cancer cases by 2050. The widespread nature of cancer worldwide is an important element stimulating the introduction of new medicines, including CAR-T cell therapy. Besides that, relaxation of a few regulatory measures has increased the use of CAR-T cell therapy.

CAR-T Cell Therapy Market Dynamics

Market Trends

The market is witnessing a shift toward first-line treatments and allogeneic platforms, as well as faster manufacturing. “Off the shelf” allogeneic CAR-T cell therapy is an emerging trend that can address supply constraints and provide quicker access to treatment. In addition, the utilization of CAR-T cell therapy for the treatment of autoimmune diseases and solid tumors is gaining significant traction.

Growth Drivers

The key growth drivers for the market include the rising incidence of cancer across the globe and the growing approvals of oncology treatments. According to the World Health Organization and the International Agency for Research on Cancer (IARC), the world cancer incidence reached 20.6 million cases in 2024. It is estimated to increase further and reach 35 million cancer instances by 2050. Moreover, the relaxation of certain regulatory restrictions has augmented the adoption of CAR-T cell therapy.

Market Restraints / Challenges

The rising cost of therapy, complexity and time along with the absence of treatment facilities are some of the hindrances to the growth of the Cell Therapy Market. The manufacturing process for autologous CAR-T treatment requires complex procedures involving the isolation of tumor cells from the patient, genetic modifications, and cell expansion.

The World Health Organization has identified the administration of CAR-T cell therapy as a significant risk factor for cytokine release syndrome, neurotoxicity, and secondary tumors. In addition, the potential risk of secondary tumors following genetically engineered T-cell infusion requires post-treatment patient monitoring. As a result, the high level of care following CAR-T cell therapy is a major challenge for treatment centers.

Market Opportunities

The market’s key opportunities lie in therapies based on allogeneic CAR-T cells, first-line treatments, and the treatment of autoimmune diseases. In this respect, the allogeneic segment will grow at a rate of 15.22% CAGR between 2026 and 2031, faster than the autologous category. Such therapy development may address manufacturing delays and promote widespread clinical use. It should also be noted that there is a growing emphasis on expanding the use of CAR-T cell therapy into treating a broader range of diseases, particularly outside of traditional hematologic malignancies. The National Cancer Institute stated in its January 2025 statement that children with diffuse midline gliomas achieved objective reductions in tumor burden after receiving experimental GD2 CAR-T therapy.

Global CAR-T Cell Therapy Market Report Coverage

CAR-T Cell Therapy Market Segmentation

By Target Antigen

CD19 was the largest target antigen in 2025, with 46.05% of the market revenue, followed by BCMA and others. This segment holds the most significant share due to the well-established role of CD19 in a wide range of B-cell malignancies along with the availability of commercial therapies.

The BCMA segment is the fastest-growing, with a projected CAGR of 14.02% during 2026 to 2035 due to the growing use of CAR-T Cells in the treatment of multiple myeloma.

By Cell Source

Autologous cell sources occupied 91.25% of the overall market revenue in 2025, and the segment is anticipated to maintain its lead through 2035. This segment holds the highest share due to the availability of an established regulatory pathway and considerable physician knowledge regarding the application of CAR-T Cell therapy in the treatment of various malignancies.

Allogeneic cell source is forecasted to witness the highest growth of 15.22% during 2026 to 2035 due to developments in manufacturing and treatment protocols that have led to a better understanding of Allogeneic cell source, reducing the treatment cost and the required time between manufacturing and administration.

By Indication

In 2025, the Lymphoma segment accounted for 54.05% of the overall revenue due to the extensive presence of the CAR-T Cell across a range of lymphoma subtypes and its established role as first-line treatment in a variety of lymphoma subtypes.

Multiple Myeloma indication will register the highest CAGR of 14.18% during 2026 to 2035. This is mainly due to the rising adoption of BCMA-targeted CAR-T Cell Therapy and the growing presence of the therapy as a first-line treatment.

By End User

In 2025, the hospitals segment accounted for 66.10% of the overall market revenue supported by the intricate and involved nature of CAR-T Cell treatment, requiring facilities to have the infrastructure and resources for successful treatment.

The Cancer care treatment centers segment is anticipated to witness the highest growth of 15.20% during 2026 to 2035, due to the rise in clinical trials and next-gen CAR-T Cell Therapies.

Regional Insights

North America

North America held the largest share of the market with a regional market penetration level amounting to 52.10% in 2025. The well-established reimbursement policies, wide treatment-center networks, as well as early approvals are some of the important factors fueling the regional growth. The delisting of REMS procedure by the US FDA for the approved autologous CAR-T products in 2025 will further reduce the administrative burden for treatment centers authorize to administer these therapies. This may lead to an increased presence of CAR-T treatment options outside academic medical centers and into community oncology settings.

Europe

Europe accounted for the second-largest share of 18.00% in 2025. The regional market is anticipated to benefit from robust oncology treatment infrastructure, strong research and development activity, as well as continued expansion into cellular therapy treatments. Europe is projected to see consistent growth driven by the harmonization of regulatory guidelines as well as decentralized manufacturing strategies. In addition, the regional demand for CAR-T therapies is supported by government-led research and advanced-therapy treatment networks. The overarching advanced-therapy regulatory framework provided by the EMA accelerates the evaluation process at a regional level, while national-level reimbursement policies are also contributing to market growth in Germany, France, the UK, and the rest of Europe.

Asia Pacific

The Asia Pacific region with 8% share is set to deliver the highest projected CAGR of 15.55% through 2035, fueled by the growing domestic expertise in cellular immunotherapy, as well as treatment manufacturing capabilities across China, Japan, South Korea, and Australia. Government-led initiatives as well as the establishment of advanced therapy manufacturing centers are also facilitating the regional expansion. Notably, China’s National Medical Products Administration, as well as Japan’s regulatory agencies, have implemented strategic initiatives supporting the local development of cellular immunotherapy. In addition, local manufacturing capabilities are helping reduce the region’s reliance on imported therapies, which in turn supports broader clinical adoption of CAR-T treatments.

Rest of the World

The Rest of the world accounted for 1.80% of the market in 2025. However, the regional market is projected to grow at a steady rate through 2035, with a CAGR of 11.50% with continued improvement in oncology care infrastructure as well as strategic collaboration with academic medical centers, Brazil and Middle Eastern markets contributing to the increasing accessibility of CAR-T treatments. It is noteworthy that treatment centers across these countries are still limited, and therefore, the regional market penetration remains under the influence of these factors. The remaining share is reserved for the smaller developing countries.

Competitive Landscape / Company Insights

The market is moderately competitive with most of the major players focusing on approvals, capacity building for manufacturing, earlier line of indications and next-gen allogeneic cell platforms to fuel competitive advantages. In addition, the industry players are investing heavily in cell engineering, automation in manufacturing, and treatment center networks to build their presence in the market. Moreover, the delisting of FDA’s REMS requirements by the U.S. FDA in 2025 and the relaxation of cell and gene therapy manufacturing requirements by the agency in January 2026 is also impacting the competitive landscape. Key government agencies driving the market include U.S. FDA, National Cancer Institute, and the European Medicines Agency, among others.

Mini Profiles

Autolus Therapeutics focuses on engineered T-cell therapies, supported by its AUCATZYL CAR-T platform, specialized manufacturing capabilities and growing commercial infrastructure for relapsed or refractory B-cell acute lymphoblastic leukemia.

Bristol Myers Squibb operates major CAR-T franchises through Breyanzi and Abecma, emphasizing expanded indications, manufacturing capacity and broader access across specialized oncology treatment networks.

Caribou Biosciences leverages CRISPR genome-editing technology to develop allogeneic CAR-T therapies, focusing on off-the-shelf treatment models designed to improve availability, scalability and treatment speed.

Gilead Sciences develops and commercializes CAR-T therapies through Kite, with Yescarta and Tecartus supported by global manufacturing, clinical development and extensive treatment-center infrastructure.

Johnson & Johnson focuses on CARVYKTI through its collaboration with Legend Biotech, supported by expanding manufacturing capacity, clinical development and earlier-line multiple-myeloma applications.

Key Players

• Allogene
• Therapeutics
• Autolus
• Therapeutics
• Bristol Myers Squibb
• Caribou Biosciences
• Gilead Sciences
• Johnson & Johnson
• Legend Biotech
• Novartis
• Precision
• BioSciences Servier

Recent Developments

Allogene Therapeutics reported progress in its ALPHA3 Phase 2 trial of cema-cel as first-line consolidation treatment for large B-cell lymphoma. The company also continued the RESOLUTION trial of ALLO-329 for autoimmune diseases, with proof-of-concept data planned for 2026.

Legend Biotech reported more than 10,000 patients treated with CARVYKTI and full-year 2025 net trade sales of approximately USD 1.9 billion. The company also expanded its Raritan manufacturing facility and advanced allogeneic and in-vivo CAR-T programs.

Caribou Biosciences reported full-year 2025 progress for its allogeneic CAR-T portfolio, highlighting vispa-cel data and continued development toward pivotal testing. The company also reported FDA engagement regarding the pivotal trial design.

Novartis presented new CAR-T biomarker data at the American College of Rheumatology meeting, supporting investigation of CAR-T approaches in autoimmune disease. The development demonstrates expansion of CAR-T research beyond conventional oncology applications.

Precision BioSciences received an USD 8 million milestone payment connected with Imugene's clinical and regulatory progress for azer-cel, its allogeneic CAR-T program. FDA discussions also provided alignment on requirements for advancing azer-cel toward pivotal development.

Table of Contents for CAR-T Cell Therapy Market Report

1.    Research Overview

        1.1.    The Report Offers
        1.2.    Market Coverage
                  1.2.1.    By Target Antigen 
                  1.2.2.    By Cell Source 
                  1.2.3.    By Indication 
                  1.2.4.    By End User 
        1.3.    Research Phases
        1.4.    Limitations
        1.5.    Market Methodology
                  1.5.1.  Data Sources
                             1.5.1.1. Primary Research
                             1.5.1.2. Secondary Research
                  1.5.2.  Methodology
                             1.5.2.1. Data Exploration
                             1.5.2.2. Forecast Parameters
                             1.5.2.3. Data Validation
                             1.5.2.4. Assumptions
                  1.5.3.  Study Period & Data Reporting Unit

2.    Executive Summary

3.    Industry Overview

       3.1.    Industry Dynamics
                 3.1.1.    Market Growth Drivers
                 3.1.2.    Market Restraints
                 3.1.3.    Key Market Trends
                 3.1.4.    Major Opportunities
       3.2.    Industry Ecosystem
                 3.2.1.    Porter’s Five Forces Analysis
                 3.2.2.    Recent Development Analysis
                 3.2.3.    Value Chain Analysis
       3.3.    Competitive Insight
                 3.3.1.    Competitive Position of Industry Players
                 3.3.2.    Market Attractive Analysis
                 3.3.3.    Market Share Analysis

4.    Global Market Estimate and Forecast

       4.1.    Global Market Overview
       4.2.    Global Market Estimate and Forecast to 2035

5.    Market Segmentation Estimate and Forecast

       5.1.    By Target Antigen 
                 5.1.1. CD19
                           5.1.1.1. Market Definition
                           5.1.1.2. Market Estimation and Forecast to 2035
                 5.1.2. BCMA
                           5.1.2.1. Market Definition
                           5.1.2.2. Market Estimation and Forecast to 2035
                 5.1.3. CD22
                           5.1.3.1. Market Definition
                           5.1.3.2. Market Estimation and Forecast to 2035
                 5.1.4. GD2
                           5.1.4.1. Market Definition
                           5.1.4.2. Market Estimation and Forecast to 2035
                 5.1.5. HER2
                           5.1.5.1. Market Definition
                           5.1.5.2. Market Estimation and Forecast to 2035
                 5.1.6. PSMA
                           5.1.6.1. Market Definition
                           5.1.6.2. Market Estimation and Forecast to 2035
                 5.1.7. Multi-Target / Tandem
                           5.1.7.1. Market Definition
                           5.1.7.2. Market Estimation and Forecast to 2035
                 5.1.8. Others
                           5.1.8.1. Market Definition
                           5.1.8.2. Market Estimation and Forecast to 2035

       5.2.    By Cell Source 
                 5.2.1. Autologous
                           5.2.1.1. Market Definition
                           5.2.1.2. Market Estimation and Forecast to 2035
                 5.2.2. Allogeneic
                           5.2.2.1. Market Definition
                           5.2.2.2. Market Estimation and Forecast to 2035

       5.3.    By Indication 
                 5.3.1. Leukemia
                           5.3.1.1. Market Definition
                           5.3.1.2. Market Estimation and Forecast to 2035
                 5.3.2. Lymphoma
                           5.3.2.1. Market Definition
                           5.3.2.2. Market Estimation and Forecast to 2035
                 5.3.3. Multiple Myeloma
                           5.3.3.1. Market Definition
                           5.3.3.2. Market Estimation and Forecast to 2035
                 5.3.4. Autoimmune Disorders
                           5.3.4.1. Market Definition
                           5.3.4.2. Market Estimation and Forecast to 2035
                 5.3.5. Others
                           5.3.5.1. Market Definition
                           5.3.5.2. Market Estimation and Forecast to 2035

       5.4.    By End User 
                 5.4.1. Hospitals
                           5.4.1.1. Market Definition
                           5.4.1.2. Market Estimation and Forecast to 2035
                 5.4.2. Cancer Care Treatment Centers
                           5.4.2.1. Market Definition
                           5.4.2.2. Market Estimation and Forecast to 2035
                 5.4.3. Academic & Research Institutes
                           5.4.3.1. Market Definition
                           5.4.3.2. Market Estimation and Forecast to 2035

6.   North America Market Estimate and Forecast

      6.1.    By Target Antigen   
      6.2.    By Cell Source   
      6.3.    By Indication   
      6.4.    By End User   
                6.4.1.     U.S. Market Estimate and Forecast
                6.4.2.     Canada Market Estimate and Forecast
                6.4.3.     Mexico Market Estimate and Forecast

7.   Europe Market Estimate and Forecast

      7.1.    By Target Antigen   
      7.2.    By Cell Source   
      7.3.    By Indication   
      7.4.    By End User   
                7.4.1.     Germany Market Estimate and Forecast
                7.4.2.     France Market Estimate and Forecast
                7.4.3.     U.K. Market Estimate and Forecast
                7.4.4.     Italy Market Estimate and Forecast
                7.4.5.     Spain Market Estimate and Forecast
                7.4.6.     Russia Market Estimate and Forecast
                7.4.7.     Rest of Europe Market Estimate and Forecast

8.   Asia-Pacific (APAC) Market Estimate and Forecast

      8.1.    By Target Antigen   
      8.2.    By Cell Source   
      8.3.    By Indication   
      8.4.    By End User   
                8.4.1.     China Market Estimate and Forecast
                8.4.2.     Japan Market Estimate and Forecast
                8.4.3.     India Market Estimate and Forecast
                8.4.4.     South Korea Market Estimate and Forecast
                8.4.5.     Rest of Asia-Pacific Market Estimate and Forecast

9.   Rest of the World (RoW) Market Estimate and Forecast

      9.1.    By Target Antigen   
      9.2.    By Cell Source   
      9.3.    By Indication   
      9.4.    By End User   
                9.4.1.     Brazil Market Estimate and Forecast
                9.4.2.     Saudi Arabia Market Estimate and Forecast
                9.4.3.     South Africa Market Estimate and Forecast
                9.4.4.     U.A.E. Market Estimate and Forecast
                9.4.5.     Other Countries Market Estimate and Forecast

10.  Company Profiles

       10.1.   Allogene Therapeutics
                  10.1.1.    Snapshot
                  10.1.2.    Overview
                  10.1.3.    Offerings
                  10.1.4.    Financial Insight
                  10.1.5.    Recent Developments
       10.2.   Autolus Therapeutics
                  10.2.1.    Snapshot
                  10.2.2.    Overview
                  10.2.3.    Offerings
                  10.2.4.    Financial Insight
                  10.2.5.    Recent Developments
       10.3.   Bristol Myers Squibb
                  10.3.1.    Snapshot
                  10.3.2.    Overview
                  10.3.3.    Offerings
                  10.3.4.    Financial Insight
                  10.3.5.    Recent Developments
       10.4.   Caribou Biosciences
                  10.4.1.    Snapshot
                  10.4.2.    Overview
                  10.4.3.    Offerings
                  10.4.4.    Financial Insight
                  10.4.5.    Recent Developments
       10.5.   Gilead Sciences
                  10.5.1.    Snapshot
                  10.5.2.    Overview
                  10.5.3.    Offerings
                  10.5.4.    Financial Insight
                  10.5.5.    Recent Developments
       10.6.   Johnson & Johnson
                  10.6.1.    Snapshot
                  10.6.2.    Overview
                  10.6.3.    Offerings
                  10.6.4.    Financial Insight
                  10.6.5.    Recent Developments
       10.7.   Legend Biotech
                  10.7.1.    Snapshot
                  10.7.2.    Overview
                  10.7.3.    Offerings
                  10.7.4.    Financial Insight
                  10.7.5.    Recent Developments
       10.8.   Novartis
                  10.8.1.    Snapshot
                  10.8.2.    Overview
                  10.8.3.    Offerings
                  10.8.4.    Financial Insight
                  10.8.5.    Recent Developments
       10.9.   Precision BioSciences
                  10.9.1.    Snapshot
                  10.9.2.    Overview
                  10.9.3.    Offerings
                  10.9.4.    Financial Insight
                  10.9.5.    Recent Developments
       10.10.   Servier
                  10.10.1.    Snapshot
                  10.10.2.    Overview
                  10.10.3.    Offerings
                  10.10.4.    Financial Insight
                  10.10.5.    Recent Developments

11.    Appendix

         11.1.    Exchange Rates
         11.2.    Abbreviations

Note: Financial insight and recent developments of different companies are subject to the availability of information in the secondary domain.